Literature DB >> 22149736

Generic atorvastatin and health care costs.

Cynthia A Jackevicius1, Mindy M Chou, Joseph S Ross, Nilay D Shah, Harlan M Krumholz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22149736      PMCID： PMC3319770          DOI： 10.1056/NEJMp1113112

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  1 in total

1.  "Top 5" lists top $5 billion.

Authors:  Minal S Kale; Tara F Bishop; Alex D Federman; Salomeh Keyhani
Journal:  Arch Intern Med       Date:  2011-10-01
  1 in total
  23 in total

1.  Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.

Authors:  Ankur Pandya; Stephen Sy; Sylvia Cho; Milton C Weinstein; Thomas A Gaziano
Journal:  JAMA       Date:  2015-07-14       Impact factor: 56.272

2.  Effects of Guideline and Formulary Changes on Statin Prescribing in the Veterans Affairs.

Authors:  Adam A Markovitz; Rob G Holleman; Timothy P Hofer; Eve A Kerr; Mandi L Klamerus; Jeremy B Sussman
Journal:  Health Serv Res       Date:  2017-12       Impact factor: 3.402

3.  Establishing the correlation between statins and cough: case series report and analysis of adverse drug reactions in the international databases.

Authors:  Carla Carnovale; Paolo Pellegrino; Valentina Perrone; Marta Gentili; Tatiana Brusadelli; Stefania Antoniazzi; Alessia Speziali; Cecilia Borsadoli; Marco Pozzi; Emilio Clementi; Sonia Radice
Journal:  Eur J Clin Pharmacol       Date:  2014-09-24       Impact factor: 2.953

Review 4.  FDA Policy and Cardiovascular Medicine.

Authors:  Joseph S Ross; Aaron S Kesselheim
Journal:  Circulation       Date:  2015-09-22       Impact factor: 29.690

5.  Generic Drugs in the United States: Policies to Address Pricing and Competition.

Authors:  Ravi Gupta; Nilay D Shah; Joseph S Ross
Journal:  Clin Pharmacol Ther       Date:  2019-01-10       Impact factor: 6.875

6.  [Three types of brand name loyalty strategies set up by drug manufacturers].

Authors:  Marie-Claude PréMont; Marc-André Gagnon
Journal:  Healthc Policy       Date:  2014-11

7.  'Generic to genetic' transition in cardiovascular and neuropsychiatric drugs: opportunity for personalized medicine.

Authors:  Jorge Duconge; Gualberto Ruaño
Journal:  Pharmacogenomics       Date:  2012-07       Impact factor: 2.533

8.  HMG-CoA Reductase Inhibitors for Prevention and Treatment of Severe Sepsis.

Authors:  Joel D Mermis; Steven Q Simpson
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

9.  Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.

Authors:  Rickard E Malmström; Brian B Godman; Eduard Diogene; Christoph Baumgärtel; Marion Bennie; Iain Bishop; Anna Brzezinska; Anna Bucsics; Stephen Campbell; Alessandra Ferrario; Alexander E Finlayson; Jurij Fürst; Kristina Garuoliene; Miguel Gomes; Iñaki Gutiérrez-Ibarluzea; Alan Haycox; Krystyna Hviding; Harald Herholz; Mikael Hoffmann; Saira Jan; Jan Jones; Roberta Joppi; Marija Kalaba; Christina Kvalheim; Ott Laius; Irene Langner; Julie Lonsdale; Sven-Äke Lööv; Kamila Malinowska; Laura McCullagh; Ken Paterson; Vanda Markovic-Pekovic; Andrew Martin; Jutta Piessnegger; Gisbert Selke; Catherine Sermet; Steven Simoens; Cankat Tulunay; Dominik Tomek; Luka Vončina; Vera Vlahovic-Palcevski; Janet Wale; Michael Wilcock; Magdalena Wladysiuk; Menno van Woerkom; Corrine Zara; Lars L Gustafsson
Journal:  Front Pharmacol       Date:  2013-05-14       Impact factor: 5.810

10.  Patents associated with high-cost drugs in Australia.

Authors:  Andrew F Christie; Chris Dent; Peter McIntyre; Lachlan Wilson; David M Studdert
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.